© 2024 Alpha Spread Limited. All Rights Reserved.
www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.
You don't have any saved screeners yet
Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.
Good afternoon. This is the Chorus Call conference operator. Welcome, and thank you for joining the DiaSorin First Quarter 2023 Results Conference Call. [Operator Instructions]
At this time, I would like to turn the conference over to Mr. Carlo Rosa, CEO of DiaSorin. Please go ahead, sir.
Yes. Thank you, operator. Good morning, and welcome to the DiaSorin Quarter One 2023 results. As usual, I'm going to make my comments at a constant exchange rate, and then I will allow our CFO, Mr. Pedron then to go through the numbers in great detail. Let's start from the revenues, EUR 284 million, which is -- versus Q1 of 2022. Let's remember that there has been a change of perimeter since we have sold our Flow Cytometry business. So at constant perimeter business would be down 20%. And then there is a second factor that is clearly, COVID. COVID is down 80%, give or take, compared to what we had last year. So excluding also the COVID business and the effect of the respiratory season, which is a way that we have indicated in our guidance, then the remaining business is actually growing 3%, so in line with the company expectations.
Now let's go and discuss the revenues by technology. Let's start from the Immunodiagnostic ex-COVID, EUR 170 million, which is a growth of 6% compared to Q1 last year, with CLIA growing 9%, so a very positive trend. The reason for the good performance of CLIA is primarily related to the fact that North America continues to grow double-digit, is a result of the success of our hospital strategy and combination of specialty menus. Europe had a very strong performance in Q1. Our Immuno franchise grew 10% in most of the geographies. And this is due to the fact that testing volume in Europe really recovered from the COVID times in quarter one. So there has been an effect certainly of continuous placement of systems and again success of the hospital strategy with specialties in certain geographies in combination with increasing testing volume. So we finally see Europe going back in terms of volume to the pre-COVID times. This growth of the Immunodiagnostics franchise happened despite the headwinds that we saw in Q1 as expected in China. We saw heavy decline in January and February due to the reopening in China and the effect of less testing volume, although we saw quite a good recovery in March, which is leading us to believe that what we see in China is going to improve in quarter 2 and certainly improve in the second half of the year as we, I think, discussed when we were commenting the expectation for 2023.
Now if we move to the Molecular Diagnostic ex-COVID, it grew 6% in the quarter. We had a good contribution from the respiratory season, notwithstanding the fact that, as we have discussed, respiratory was very strong in Q4 last year. We still had a good result in quarter one, especially in the U.S. And also, we had a recovery and growth of the nonrespiratory panels. Let me remind you that as far as respiratory is concerned, our guidance which is indicating a decline of 20% year-on-year is built on the fact that the 2023-2024 season, which is what we will see in -- starting from Q4 this year is a normal flu season. And that means that probably the flu peak is going to span through quarter 4 and Q1 for next year. So Q1 for respiratory was good, better than expected. Let me also remind you that our year-end guidance for Molecular Diagnostic was built on the fact that starting from quarter 2, we are going to have the effect of the net loss of the cystic fibrosis contract, which is a very relevant contract that the company had with one of the major private labs in the U.S. Let's move to the LTG. LTG is a constant perimeter because here is where typically we were accounting for the Flow Cytometry business. So LTG at constant perimeter is down 11% compared to Q1 2022. This is expected and is a combination of different events. First, we have a different pattern of orders, which are coming from some of the strategic partners when it comes to components that they buy from us to make their own products. So we expect orders to be shifted in Q2 and Q3. It's a tough comparison with Q1 '22, this quarter, because last year, some of the orders were actually in -- concentrated more in Q1 than in quarter 2. Last but not least, we do have still a tail of chain -- supply chain issues when it comes to a component. Although I have to say that we expect this issue to be addressed and resolved in quarter 2. And therefore, we should not be seeing backorder issues starting from the next quarter. Overall, we continue to believe that year-end growth of the LTG business is going to be around 7%, 8% as indicated in our guidance.
So the quarter one result, the soft quarter one result is primarily an effect of phasing. As stated before, when it comes to COVID, 80% down compared to what it was in 2022 and in line with what we have foreseen for the 2023 guidance. Let me now comment some of the strategic programs and then Piergiorgio is going to get into the details of the numbers. So let me start from the LIAISON Plex. As we've indicated, we have concluded the clinical studies in the U.S. and we expect that we are going to file for approval in -- between quarter 3 and quarter 4 of 2022. This is for the respiratory panel and then the GI panel will follow suit in terms of clinical and submission. [indiscernible], we are starting the clinical studies in Australia for the -- just to catch the beginning of the respiratory season, and we will conclude the studies clearly in the U.S., catching now the full respiratory season, and we expect to have filing done at beginning of 2024, for U.S. approval, again, this would be Flu A, Flu B and COVID panel. When it comes to -- last but not least, I would like to discuss about MeMed. When it comes to MeMed, we have initiated a plan to accelerate adoption in the U.S. It is very clear to us that today, there are 2 barriers that we have to be overcome. One that I would say is relatively limited as to do with the availability of reimbursement from private payers. I remind everybody that the test is anyway covered under the DRG when in use in emergency room. And the second barrier to be overcome has to do with the fact that this test is to be actually properly placed in guidelines and supported by physicians. Primarily, we are talking about infectious disease specialists. And so we decided together with the Board to accelerate the investment in the U.S., starting from the second half of this year and hiring a dedicated sales force that will actually go and market the product to physicians and not to the clinical laboratory. As you know, we already have a very strong sales force in the U.S. to hit the clinical laboratory. But in this very specific case, we need to do education with physicians. And this program is going to be a combination of 3 events. One certainly is a dedicated sales force. The second event is a digital campaign, again, tailored to support adoption of this product with [indiscernible] specialists and we expect that the team is going to be set in place starting from the end of quarter 3. We see that today, there is a lot of interest from the market when it comes to this product because clinical evidence has been provided by MeMed and the initial clinical studies are -- have been published in peer-reviewed journals indicating that the intended use, which was approved by the FDA is in fact obtained by hospitals when this product is set in place in the guideline.
So we continue to be extremely positive about MeMed and we're going to give you update -- more update about the development of this market in the following quarters. PG, please go ahead and take the later numbers.
Thank you, Carlo, and good morning, good afternoon, everybody. In the next few minutes, I'm going to walk you through the financial performance of DiaSorin during the first quarter of 2022. Let me please remind you that consistently with what we did over the last calls, I will refer to adjusted P&L items, therefore, stabilizing the impact of the Luminex deal-related elements. So that as usual, I'd like to start with what I think are the main highlights of the period. So again, on revenues, Q1 '23, total revenues at a constant exchange rate decreased by 21% and whereas the decrease at the constant perimeter of consolidation, which means without the contribution of the Flow Cytometry business has been 20%. This result, as we just said, is a combination of the expected reduction in COVID sales, down by 78% in the quarter, partially offset by a growth of the ex-COVID business by 3%. This performance is in line with the full-year guidance and our expectations. During the quarter, the Ex-COVID revenues of the constant perimeter of consolidation net of the Molecular Respiratory business, which is how we gave the guidance grew by 3% as well, is a combination of a very good performance of the Immuno franchise as we have seen, partially offset by the expected slightly negative contribution of the Licensed Technology business. Q1 '23 Molecular Respiratory business grew by 9% compared to the previous year. Moving now to the EBITDA. Q1 '23 adjusted EBITDA at EUR 98 million or 34% of revenues is in line with the full-year guidance. The decrease compared to last year, EUR 52 million, or 35% is mostly attributable to the reduction in COVID sales. Lastly, during the quarter, the group generated EUR 28 million of free cash flow, therefore, recording a reduction of EUR 88 million compared to last year. This variance is mainly driven by the reduction in COVID sales and by an increase in working capital, mostly attributable to the phasing of some nonrecurring events. To be more precise, we have had some advanced cash-out of some accounts payable and delayed collection of some account receivable of our legacy molecular legal entity in the U.S. in order to manage its ERP system consolidation into the one of Luminex. This was part of our IT integration program. Then we have had some one-off payments of past accrued liabilities for the Flow Cytometry business employees who moved to the buyer of this business and then we have had an increase in input VAT, which is the result of the Italian legal entity reorganization, which you might remember took place last year. These nonrecurring events are temporary in nature and will be absorbed within the end of the year.
Before moving to the P&L, let me please provide you an update on the so-called payback system for medical devices. As you might remember, this measure originally introduced in 2015 by the Italian government and never implemented since then has been eventually reactivated in September 2022. All the operators -- basically all the operators, including the DiaSorin have filed legal appeals to the competent court to challenge the decree. To be more precise, the administrative regional court in Rome has been charged with almost 2,000 [ courses ] to suspend and invalidate the payback regulation. The payment due date originally set for January 2023 was initially postponed by the government to the end of April and has recently been postponed even further until the end of June by a law decree, which has been released by the Italian government at the very end of March. This decree has also introduced the faculty for each company to settle any disputes by paying 50% of the total amounts requested by the regions within June and by announcing any pending legal action. So according to the usual legislative process in Italy, the law decrees is currently subject to the approval of the parliament, which may impose different changes to it. In the meanwhile, the administrative regional court in Rome pending the final approval of this law decree and waiting for the decision that the companies might take has postponed the [indiscernible] set up for June 2023. In summary, the old situation is really in flux. Pending more clarity on the legal front and in the light of the recent news I've just shared with you, we have not changed the balance sheet provision booked as of the end of 2022. We will keep on monitoring the evolution of this complex and ever-changing situation and update investors during the next quarter calls. Now moving to the P&L. Q1 '23 total revenues at EUR 290 million at current exchange rate, a decrease by 19% or EUR 68 million compared to last year. This variance, as we said, is due by COVID. And we have had in the quarter some EUR 6 million FX tailwind, mainly driven by the USD appreciation compared to last year. First quarter adjusted gross profit at EUR 192 million decreased by 19% compared to last year with a ratio of revenues of 66%, in line with the same period of 2022. The carve-out of the Flow Cytometry business alongside all the initiatives aimed at improving operations, processes and containing costs, most of them part of our broader cost synergy plan allowed us to preserve margins in spite of the reduction in revenues and the tail of the inflationary pressure we talked about in 2022.
I believe this to be a remarkable indicator of the relentless efforts we put in place to safeguard margins. Q1 '23 adjusted operating expenses at EUR 150 million grew by 5% or 3% at a constant exchange rate compared to 2022, with a ratio of revenues of 40% vis-a-vis 31% of last year. The worsening of the operating leverage ratio is entirely due to the reduction in COVID sales. Starting from the second quarter, we will see the benefit coming from the Flow Cytometry business carve-out.
Adjusted operating expenses at negative EUR 2 million are substantially in line in absolute value with 2022 at a constant exchange rate. Reported other OpEx include slightly more than EUR 3 million costs related to the Flow Cytometry business carve-out. As a result of all of these elements, Q1 '23 adjusted EBIT at EUR 75 million or 26% of revenues has decreased compared to 2022 by 41% or EUR 51 million. Adjusted interest income at EUR 1 million is better than last year by EUR 3 million, mainly because of improved yield on our cash investments whereas the adjusted tax rate at 23% is in line with 2022.
Q1 adjusted net results at EUR 59 million or 20% of revenues is lower than previous year by EUR 38 million or 39%.
Let me now move to the net debt position at the end of March 2023. The net debt was negative EUR 849 million vis-a-vis negative EUR 907 million at the end of 2022. This improvement has been mostly driven by the proceeds of the sales of the Flow Cytometry business and the operating cash generated in the quarter. Lastly, we confirm 2023 guidance as usual at previous year's exchange rate. Let me remind you the guidance. Total revenues, minus 14%, total revenues at a constant perimeter of consolidation, minus 11%, of which COVID at about EUR 60 million, so down by 75%, Molecular Respiratory business, minus 20%, base business ex-COVID molecular respiratory, plus 4/plus 6%, adjusted EBITDA margin around 34%.
Please let me remind you that we have built, as Carlo just said in our assumption on average respiratory season and that 2023 guidance does not include any possible impact from the payback mechanism in Italy. Since I said a few minutes ago, our situation is really in flux. And the most recent news which are personally deemed positive and pointing in the right direction, it made even more difficult to make any reliable prediction on what is going to happen. Now let me please turn the line to the operator to open the Q&A session. Thank you.
[Operator Instructions] Our first question is from Aisyah Noor with Morgan Stanley.
My first one is on the Immuno business. Could you confirm if the latent TB testing business was the major growth driver here? Or if you saw more broad-based growth across the CLIA franchise? And then the second one is just one for Piergiorgio on the gross margin development, which was stable year-on-year despite the sales decline. Could you quantify the contribution from cost synergies, from the Luminex integration in the quarter? And is that sustainable for the rest of the year?
I'll take the first one on TB. TB, as you know, is an important assay for the DiaSorin, but I don't think that itself explains the success of the program because the success of the program comes from the fact that we have a number of products that goes along with TB and mix than the whole portfolio acceptable for the customer.
Keep in mind that especially in the U.S., we are now -- once we -- together with QIAGEN, we converted some of the large users of ELISA or the ELISA QIAGEN product. Now we are directing our effort to go after the send-out business. And this business is certainly of decent size, but not enough -- will not be enough to justify a placement. So I would say that TB -- long story short is a relevant, but not uniquely strategic product for DiaSorin to pursue its strategy in the U.S. hospital marketing. It's the strength of the portfolio that really gives value to DiaSorin, a supplier in that market.
Going to the gross margin question, so I don't believe I'm going to give the exact amount of synergies hitting our gross margin, contributing to our gross margin. But what I can share with you is that at the end of 2022, we had a run rate overall of north of $40 million synergies delivered since the acquisition. Let me remind you that the target was to get to 55 million by run rate by the end of 2023 and 60 million by the end of 2025. And I believe from everything I'm seeing that we will deliver those targets. For this reason and for all the other different initiatives that we put in place to circa margins, one of them is also to increase prices to customers. I believe the 66% gross margin we see in Q1 to be sustainable for the remainder of the year.
If I just may add consideration here. Talking about TB and the rest of the portfolio, as you can imagine, TB is overall a dilutive effort on the gross margin for DiaSorin since it is a product that is licensed and commercialized with QIAGEN. And you rightfully saw, you noticed that our gross margin continues to be elevated. But this is because -- certainly, because we continue to promote [indiscernible] products developed by DiaSorin that we enjoy the full margin potential, okay? So this is to say, TB is certainly important, but the gross margin effect has to do with the rest of DiaSorin portfolio, TB is dilutive for us.
Our next question is from Odysseas Manesiotis with Berenberg.
Could you please specify which exactly current parts in the license business are causing the shortages? And secondly, could you please share a rough estimate of how much of a price increase you managed to take through in Q1 for most of your clinical business and last one on MeMed. Have you had any pushback regarding the willingness of hospitals that are willing to adopt this under DRG to pay for the assay? And are there plans to create an unbundled path to charge insurers for inpatients in a model fashion to the DRG payment?
So I'll take the first and the last question. Let me start from the last one. Yes, absolutely so. There is a plan that has been shared with MeMed. And MeMed negotiated with some of the major players, a clinical study that is in execution as we speak, to provide evidence to obtain specific reimbursement unbundled from the DRG for this -- for the MeMed assay in the emergency room environment.
I think that we believe it's going to take probably between 18 months and 2 years by the time the study is concluded and the unbundling is obtained. This is a full and plain a responsibility of MeMed, although the clinical study is going to be conducted using also the DiaSorin product, okay. Today, there is no critical resistance to the adoption of the assay because the clinical evidence is very strong. And so as we speak, there is no resistance by hospitals per se to adopt it based on any financial consideration. I believe that, as we said before, the clinical evidence is very strong. So now it's a matter of teaching and showing the evidence to the physician who are the ones that will make the -- will prescribe the assay, right? So it's more demand generation.
On the LTG, on the parts, generally speaking, the concern that we had was -- had to do with the supply of electronic boards that were specific for our systems. And clearly, in light of the supply chain issue overall -- global supply chain issue with this component, our industry, which represents very small portion of the overall business was actually put in a holding pattern because other business -- other businesses, general goods in general and automobile clearly got the priority. It caught up. And this is, I believe, the first quarter when -- where we get pretty much on time, what we order. And the other element, which I think is relevant is that, let me call it, properly -- owning properly a black market, meaning that until today, during shortage, some of these components became unavailable on the market with the exception of some interesting suppliers that popped up all of a sudden, at the cost clearly with limited quantities and costs that were 30%, 40% higher than what the open market we're supplying to. I believe that also this phenomenon is dying because on the regular market, now you find part at the proper price. So from what we have seen so far, there has been a tail, but this tail is closing.
When it comes to price increase, I believe that we have already communicated that as far as LTG is concerned, we followed what our partners gave to the end user market in terms of price increase, which is in the range of 4%, 5%. And therefore, we have increased our pricing to them by pretty much the same amount to cover for all the inflationary costs that we had to experience clearly as everybody else in the manufacturing process.
Our next question is from Maja Pataki with Kepler.
I have 3, please. The first one, Carlo, on the -- under really solid growth that you've had in Immunodiagnostics and also Molecular ex-respiratory and ex-COVID. You mentioned in your opening remarks that we're back at pre-COVID levels. And I'm just wondering, has there been any negative impact in Q1 2022 were based testing has been still a bit subdued due to COVID? Or is that really a clean growth number? And if so, could you maybe say why you think that volumes are now back at the past or the momentum that they were before? The second question is around the cost for the program that you're launching to really promote MeMed more as of Q3, Q4. Could you give us a ballpark number, how much that going to be? Or is it not material? And then the last question when it comes to the pattern, the order pattern for LTGs, shall we also assume that the quarterly revenues are going to be more lumpy and more volatile? Or is it just something that has been a transition in Q1 and now is going to normalize?
Okay. Let me start on the volume question. I'm going to be very specific. I was referring to volume increase in specifically in the European countries because what we saw is across all European countries and across very different product lines, we saw an increase in volume. And we went back and we compare testing volume at certain sites to what the testing volume used to be in 2019 and we saw that for most of these hospitals, now we are going back to that level. It means, as I said before, that we certainly had an increase in Q1 compared to Q1 2022 because in Q1 2022, we were still suffering from reduced volume because of COVID, okay? Let's be clear.
So the growth that we saw in Europe, U.S., we didn't see the same effect. I'm specifically referring to the European situation, where the business in Q1 grew 10% in Immuno. There is a component to it, which is a volume recovery that we believe certainly will continue short term. So also in the next few months would -- but at a certain point, it's going to be leveling off because also in 2022, in the second part, there was a recovery of volume.
The second question is related to the MeMed so-called marketing effort, Maja, ballpark $5 million in 2023 which is a combination of digital campaign and hiring of sales force -- clinical sales force. The third question you have, I believe, has to do with LTG. The LTG business is B2B primarily, as you know. So it is bumpy by nature. So I believe that you're going to see a recovery starting from quarter 2 because we have certain orders, the cadence of some of the orders will happen in quarter 2. And then you may see some bumpiness in Q3 and Q4. But overall, we expect that by year-end, we are going to get to the 7%, 8%, which was indicated by the guidance. There's no signal or reason to doubt that. The other element, which is very interesting, we have -- which is also strengthening, this argument is the fact that part of our revenues are coming from royalties. And the royalties are an indication of the end-user business of our partners. And we see that the royalties are actually increasing mid-single digit, which is telling you that the bumpiness we see in Q1 is to do more to the ordering pattern of the component from us rather than the end user business, which continues to increase as normal.
Our next question is from Shubhangi Gupta with HSBC.
So first, can you please talk about the market size of this MeMed that differentiate between viral and bacterial infections and second, as you mentioned, regarding LTG, so you are seeing increase in royalty business. So is there any difference in gross margin of this segment compared to others? And the third one is related to product delays. So you have been facing some product delays, including like VERIGENE and LIAISON XS. Can you sort of give a timeline on that?
Okay. Let's start from the one I remember. So the product delays, you are saying the LIAISON XS, I don't think we had -- LIAISON XS was actually launched few years ago. So I think you are referring more to the LIAISON Plex. And the LIAISON Plex and LIAISON NES, I believe that during this call, I've given an indication of the fact of where the project statuses, status of the clinical study, which again has been completed for the Plex. And so we are compiling document for submission. And then on the NES, where we start the clinical study in Australia. When it comes to the MeMed market size, I think that there are different ways to slice this onion, if I -- or peel this onion and I'll try to make it simple for you. If you look at one segment that we believe is the one that can be readily captured which is testing of kits in emergency room showing with fever without origin, right, is what we're talking about. In the U.S., there are roughly 5 million admissions every year. And in Europe, pretty much almost the same, 4.5 million. So just to make my calculation simpler, I assume that you have 10 million admission and that is defining the market size for this product. Then you multiply by a price that I don't think we never disclosed and so you need to figure it out from what some of the analysts have actually projected. And you come up with a market just for kits that can be measured in hundreds of millions of dollars or euros, depending on the currency that you like.
The third question has to do with the LTG. And sorry, I don't...
About the margins. If we can say something about the margins of the LTG business.
No, I don't think I can specifically say anything about the margins of the LTG business, except for a qualitative remark, as you can understand that there is a component to this business, which is royalty. And then there is another component of this business, which is a reagent. And then there is a third one, which is instruments. Okay. Without sounding funny, the royalty margin is clearly 100%. The component business is very similar to the margins that we experience today with our Immuno SA franchise, so it's elevated. And when it comes to instruments, which is a means to an end for us is a way to provide to our users the ability actually to run their products and generate revenues or royalties and use components, we are talking about a margin that is relatively low. But again, our margins, we are not a company that makes money selling instruments even in the LTG. We make our margins by helping our partners to sell products and some royalties and then providing them with components.
Mr. Rosa, gentlemen, there are no more questions registered at this time.
Thank you, operator. Bye-bye.